<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4414">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04516564</url>
  </required_header>
  <id_info>
    <org_study_id>AK119-101</org_study_id>
    <nct_id>NCT04516564</nct_id>
  </id_info>
  <brief_title>A Study of AK119 (Anti-CD73 Antibody), a Treatment for COVID-19, in Healthy Subjects</brief_title>
  <official_title>A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, First-In-Human Study Evaluating the Safety, Tolerability, and Pharmacokinetics of AK119 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Akesobio Australia Pty Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Akeso</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a first-in-human (FIH), Phase 1, single-center, randomized, double-blind,&#xD;
      placebo-controlled, single ascending dose study to evaluate the safety, tolerability, PK and&#xD;
      immunogenicity of AK119, a humanized monoclonal antibody targeting the CD73. The study will&#xD;
      consist of 4 cohorts of healthy subjects. Eight subjects will be enrolled per cohort,&#xD;
      randomized in a 3:1 ratio to receive a single dose of either the active drug AK119 (N=6) or&#xD;
      matching placebo (N=2). Approximately 32 subjects (24 receiving active drug and 8 receiving&#xD;
      placebo) will participate in this study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">September 2020</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-emergent AEs</measure>
    <time_frame>From signing of informed consent till end of study (approximately 64 days postdose)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum serum concentration (Cmax) of AK119</measure>
    <time_frame>From baseline till end of study (approximately 64 days postdose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve (AUC) of serum concentration of AK119</measure>
    <time_frame>From baseline till end of study (approximately 64 days postdose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects who develop detectable anti-drug antibodies (ADAs)</measure>
    <time_frame>From baseline till end of study (approximately 64 days postdose)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Coronavirus Disease 2019 (COVID-19)</condition>
  <arm_group>
    <arm_group_label>AK119</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of AK119 is administered via intravenous infusion to healthy subjects.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of placebo is administered via intravenous infusion to healthy subjects.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AK119</intervention_name>
    <description>Single dose of AK119 is administered via intravenous infusion to healthy subjects</description>
    <arm_group_label>AK119</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single dose of placebo is administered via intravenous infusion to healthy subjects</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Subjects must meet ALL the following inclusion criteria (as applicable) to be eligible for&#xD;
        participation in this study:&#xD;
&#xD;
          -  Adults between 18 and 55 years of age, inclusive, at screening.&#xD;
&#xD;
          -  Must have a calculated body mass index (BMI, weight [kg]/height [m2]) within 18.0 to&#xD;
             30.0 kg/m2 (inclusive) at screening, and a total body weight ≥50 kg for men or ≥45 kg&#xD;
             for women at screening and Day -1 before randomization.&#xD;
&#xD;
          -  Must, in the opinion of the Investigator, be in good general health based upon medical&#xD;
             history, physical examination (including vital signs), and 12-lead ECG; and clinical&#xD;
             laboratory tests (up to 1 repeat permitted) must fall within the clinical laboratory&quot;s&#xD;
             reference normal ranges.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects who meet ANY of the following exclusion criteria will not be enrolled in this&#xD;
        study&#xD;
&#xD;
          -  Have a history of latent or active granulomatous infection, including histoplasmosis,&#xD;
             candidiasis, or coccidioidomycosis prior to screening, or a history of any other&#xD;
             infectious disease within 4 weeks prior to screening that, in the opinion of the&#xD;
             Investigator, affects the subject&quot;s ability to participate in the study.&#xD;
&#xD;
          -  Have a history of multiple drug allergies or a known allergy or hypersensitivity to&#xD;
             any biologic therapy at screening that is important in the opinion of the&#xD;
             Investigator.&#xD;
&#xD;
          -  Have a known allergy or reaction to any component of the AK119 formulation.&#xD;
&#xD;
          -  Have any known malignancy or have a history of malignancy within the previous 5 years.&#xD;
&#xD;
          -  Have a 12-lead ECG demonstrating QTcF interval &gt; 450 msec for male subjects and &gt;470&#xD;
             msec for female subjects at screening and Day -1 from average of 3 ECGs obtained after&#xD;
             5 minutes of supine rest.&#xD;
&#xD;
          -  Blood pressure (BP) &gt;150 mmHg (systolic) or &gt; 95 mmHg (diastolic) at screening and Day&#xD;
             -1, following at least 5 minutes of supine rest.&#xD;
&#xD;
          -  Have had a live vaccination within 12 weeks prior to the study dosing or intend to&#xD;
             have a live vaccination during the course of the study or have participated in a&#xD;
             vaccine clinical study within 12 weeks prior to the study dosing.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kon Yew Kwek, BMBCh, DPhil</last_name>
    <phone>+86 (0760) 8987 3999</phone>
    <email>global.trials@akesobio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Christchurch Clinical Studies Trust</name>
      <address>
        <city>Christchurch</city>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Chris Wynne</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>August 13, 2020</study_first_submitted>
  <study_first_submitted_qc>August 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 18, 2020</study_first_posted>
  <last_update_submitted>September 18, 2020</last_update_submitted>
  <last_update_submitted_qc>September 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anti-CD73</keyword>
  <keyword>immunotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

